Heidelberg Pharma AG Stock
Heidelberg Pharma AG Stock
The Heidelberg Pharma AG price is unchanged compared to yesterday.
So far the community has only identified positive things for Heidelberg Pharma AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 0.000% | -2.422% | -9.325% | 16.529% | 18.987% | -53.311% | -52.525% |
| Nanorepro AG | -1.950% | 0.984% | -4.938% | 8.451% | 16.226% | -37.903% | -58.152% |
| Vivoryon Therapeutics N.V. | -1.490% | -2.430% | -3.019% | -20.100% | -19.620% | -85.185% | -82.581% |
| Vaxart Inc. | 0.070% | -1.958% | -26.211% | -52.834% | -58.398% | -73.770% | -95.441% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma